31 results about "Acetyl cholinesterase" patented technology

A method for treating the adverse effects of acetyl-cholinesterase inhibitors used in the treatment of cognitive disorders such as acute delirium and cognitive impairment in elderly human patients. The administration of a clinically effective amount of a quaternary ammonium anti-cholinergic muscarinic receptor antagonist having very low lipid solubility substantially eliminates the adverse effects of urinary and/or fecal incontinence, nausea, bradycardia, bronchorrhea or brochospasm caused by the acetyl-cholinesterase inhibitors, without affecting the beneficial activity of the acetyl-cholinesterase inhibitors. This permits the administration of the optimum effective dosing of acetyl-cholinesterase inhibitors to provide maximum benefit to the patient with the added benefit of reducing or eliminating the unwanted side effects of fecal and urinary incontinence. Further, the combination of rivastigmine and glycopyrrolate has been effective in significantly improving cognitive function in patients suffering from acute dementia or cognitive impairment.

There is disclosed a method of treating various diseases caused by micro-vasculature circulation problems, including, but not limited to, vascular insufficiency, phantom pain, diabetic neuropathy, neuropathic pain, autoimmune/inflammatory diseases (e.g., multiple sclerosis, Parkinson's disease, Crohn's Disease, lupus, rheumatoid arthritis, polymyalgia rheumatica, polymyositis, dermatomyositis, sarcoidosis), urinary retention, lymphoedema, and chronic renal insufficiency. Specifically, there is disclosed a treatment providing an effective amount of an acetyl cholinesterase inhibitor compound (or combination of compounds) to treat one or a plurality of microvasculature diseases.

A group of indolealkylamino-withasteroid conjugates, isolated and purified from Withania somnifera, are described. A synthetic method of making an indolealkylamino-withasteroid compound is provided. In vitro acetyl cholinesterase inhibitory activity and methods for treatment of dementia and dementia-related disorders, such as Alzheimer's disease, and anxiety and depressive disorders in mammals are demonstrated with these novel compositions.

The invention discloses a piperazine compound and application of the piperazine compound served as a calcium channel blocker or/and an acetyl cholinesterase inhibitor.

The invention discloses 7H-benzo-isoxazole-[7,6-e][1,3]oxazine derivatives as shown in the formula I or pharmaceutically acceptable hydrates/salts thereof, and further discloses stereoisomers or tautomers of the 7H-benzo-isoxazole-[7,6-e][1,3]oxazine derivatives. According to the formula I, R1 represents a hydrogen group, a methyl group, an ethyl group, a halogen group, a methoxyl group, an ethoxy group, a nitro group or an alkoxyl group. The 7H-benzo-isoxazole-[7,6-e][1,3]oxazine derivatives have an obvious effect in inhibiting acetyl cholinesterase, and can be used for enhancing the memory of patients suffering from dementia and the Alzheimer's disease. The invention further relates to preparation methods of the derivatives and application of the derivatives to preparation of medicine used for treating the Alzheimer's disease.

The invention relates to the technical field of electrochemical analysis, in particular to an AchE/GQDs/N-F-TiO2Ns photoelectrochemical biosensor preparation method and application thereof. The AchE/GQDs/N-F-TiO2Ns photoelectrochemical biosensor comprises GQDs/N-F-TiO2Ns and AchE, wherein the GQDs/N-F-TiO2Ns comprises a nitrogen and fluorine-doped titanium dioxide nanotube array (N-F-TiO2Ns) and graphene quantum dots (GQDs) modified on the titanium dioxide nanotube array; cross-linking modification of acetyl cholinesterase (AchE) on the GQDs/N-F-TiO2Ns is carried out; the wavelength at the highest photocurrent response of the photoelectrochemical biosensor is 365 nm; and cross-linking modification of the AchE on the GQDs/N-F-TiO2Ns is carried out through chitosan. The modification of the graphene quantum dots improves the photocurrent intensity. Due to the good biocompatibility, the immobilization of the enzyme on an electrode is improved, and the affinity of the enzyme to a substrateis improved at the same time. the method can also be used in detection study related to acetylcholine and acetyl cholinesterase.

The invention relates to the field of biochemical detection, in particular to an organophosphorus detection method based on LSPR (localized surface plasma resonance). According to the method, an organophosphorus sample is sufficiently contacted with an acetyl-cholinesterase immobilized sensing chip, and an organophosphorus inhibiting enzyme film is formed on the surface of the sensing chip; the sensing chip containing the organophosphorus inhibiting enzyme film is immersed into a mixed solution of acetylthiocholine and chloroauric acid for a sufficient reaction, and gold nanoparticles are formed on the surface of the sensing chip; the sensing chip containing the gold nanoparticles is irradiated by visible light or infrared light, and an extinction spectrum of transmission light is measured, and an LSPR spectrum is acquired; the LSPR spectrum is compared with a standard LSPR spectrum, whether the organophosphorus sample contains organophosphorus is determined according to deviation of absorption peak; the concentration of the organophosphorus is determined according to displacement of the absorption peak. Metal nanoparticles are not required to be prepared before the acetyl-cholinesterase film is immobilized, the detection process is simplified, and low cost is realized.

The invention relates to a heterocyclic compound for treating Alzheimer disease and a preparation method thereof. The heterocyclic compound has a good effect of inhibiting the activity of acetyl cholinesterase; as proved by a behavioral experiment research of a senescence-accelerated mouse (SAM-P/8), the heterocyclic compound can effectively improve the memory function of the SAM-P/8 mouse, so that the heterocyclic compound can be used for treating cognitive dysfunction and/or neural degeneration dementia with abnormal protein aggregation, particularly the Alzheimer disease.

Pharmaceutical compositions and combinations containing a muscarinic receptor antagonist, such as oxybutynin in a transdermal therapeutic system, and a muscarinic receptor agonist, optionally with an acetyl cholinesterase inhibitor, and methods of using the same for treatment of hypocholinergic disorders of the central nervous system such as Alzheimer type dementia. The respective pharmaceutical compositions and combinations of the present invention allow for safe administration of high doses of muscarinic receptor agonist, and improved efficacy of the muscarinic receptor agonist for treatment of hypocholinergic disorders of the central nervous system. The pharmaceutical compositions and combinations also allow for a maximum supply of acetylcholine to the central nervous system, when an acetyl cholinesterase inhibitor is used in combination with a muscarinic receptor antagonist and a muscarinic receptor agonist.

A combination of a non-selective, peripheral anticholinergic agent, and a muscarinic receptor agonist, optionally with an acetyl cholinesterase inhibitor, and method of using the same for the treatment of hypocholinergic disorders of the central nervous system. The combination of the present invention allows for safe administration of high doses of muscarinic receptor agonist, and improved efficacy of the muscarinic receptor agonist for treatment of hypocholinergic disorders of the central nervous system. The combination also allows for a maximum supply of acetylcholine to the central nervous system, when an acetyl cholinesterase inhibitor is used in combination with a non-selective, peripheral anticholinergic agent and a muscarinic receptor agonist.